Kiniksa Pharmaceuticals Ltd (KNSA) Stock Analysis

Kiniksa Pharmaceuticals Ltd (KNSA) is a publicly traded company in the HEALTHCARE sector. It trades at $46.92, carries a market capitalization of $3.73B, a price-to-earnings ratio of 53.22. This page summarizes the public market data, fundamentals, and frequently asked questions for KNSA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $46.92
• Market Cap: $3.73B
• P/E Ratio: 53.22
• EPS: $0.91
• 52-Week High: $59.87
• 52-Week Low: $26.27

Market Sentiment

Kiniksa Pharmaceuticals Ltd currently has a Neutral sentiment score of 0.14.

About Kiniksa Pharmaceuticals Ltd

None

GNG Research Analysis

GNG Research scores Kiniksa Pharmaceuticals Ltd (KNSA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KNSA.

Frequently Asked Questions

Does KNSA pay dividends?

Kiniksa Pharmaceuticals Ltd (KNSA) does not currently pay a regular dividend.

What is KNSA's P/E ratio?

Kiniksa Pharmaceuticals Ltd has a price-to-earnings (P/E) ratio of 53.22.

What is KNSA's market cap?

Kiniksa Pharmaceuticals Ltd (KNSA) has a market capitalization of $3.73B with a current stock price of $46.92.